Biomarkers in Urine Samples From Patients With Wilms Tumor
The recruitment status of this study is unknown because the information has not been verified recently.
Verified April 2012 by National Cancer Institute (NCI).
Recruitment status was Active, not recruiting
Information provided by:
National Cancer Institute (NCI)
First received: March 6, 2012
Last updated: April 25, 2012
Last verified: April 2012
RATIONALE: Studying samples of urine from patients with cancer in the laboratory may help doctors identify biomarkers related to cancer.
PURPOSE: This clinical trial studies biomarkers in urine from patients with Wilms tumor.
Genetic: proteomic profiling
Other: enzyme-linked immunosorbent assay
Other: laboratory biomarker analysis
Other: medical chart review
||Discovery and Validation of Wilms Tumor Markers Using Urine Proteomics
Primary Outcome Measures:
- Wilms tumor biomarkers identified by ELISA [ Designated as safety issue: No ]
| Estimated Enrollment:
| Study Start Date:
| Estimated Primary Completion Date:
||April 2012 (Final data collection date for primary outcome measure)
- To validate the prognostic performance of specific-candidate Wilms tumor markers by measuring their urinary concentration using enzyme-linked immunosorbent assays (ELISAs) in urine specimens collected at diagnosis from 50 patients with favorable histology Wilms tumor who relapsed and 50 patients who did not relapse.
OUTLINE: Urine specimens are analyzed using enzyme-linked immunosorbent assays (ELISAs) for biomarkers.
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
- Urine specimens collected at diagnosis will be selected from patients with stage II-III Wilms tumors, with both local and non-local sites of disease relapse
- Clinical patient information (urinalysis/macro, age, gender, congenital defects/syndromes, comorbidities, tumor stage, size, pathology, therapy, outcome) available
PRIOR CONCURRENT THERAPY:
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01550393
Children's Oncology Group
||Elizabeth A. Mullen, MD
||Dana-Farber Cancer Institute
No publications provided
||Peter C. Adamson, Children's Oncology Group - Group Chair Office
History of Changes
|Other Study ID Numbers:
|Study First Received:
||March 6, 2012
||April 25, 2012
||United States: Federal Government
Keywords provided by National Cancer Institute (NCI):
stage II Wilms tumor
stage III Wilms tumor
recurrent Wilms tumor and other childhood kidney tumors
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on July 23, 2014
Carcinoma, Renal Cell
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Complex and Mixed
Neoplastic Syndromes, Hereditary
Genetic Diseases, Inborn